+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID06038058

A Phase I Study of BRY812 Injection to Assess Safety and Effectiveness in Adults With Advanced Cancers

Led by BioRay Pharmaceutical Co., Ltd. · Updated on 2025-12-30

164

Participants Needed

1

Research Sites

17 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating BRY812 for injection in patients with advanced malignancies in this Phase I, multicenter, open-label, single-arm clinical study. The study aims to assess the safety, tolerability, how the drug moves through the body, its anti-tumor effects, and immune response in patients with advanced solid tumors who have not responded to or cannot tolerate standard treatments. This first-in-human trial is sponsored by BioRay Pharmaceutical Co., Ltd.

CONDITIONS

Brief Title

A Study of BRY812 for Injection Alone in Subjects With Advanced Malignancies

Research Team

H

He rui Yao, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here